Pulmonary Drug Delivery Systems Market, By Product Type, By Application, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Title:
Pulmonary Drug Delivery Systems Market, By Product Type (Nebulizers, MDIs, DPIs), By Application (Asthma, COPD, Cystic Fibrosis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Orally inhaled and nasal drug products (OINDPs) are the products which include metered dose (MDIs), dry powder inhalers (DPIs), nasal sprays and nebulizers. According to FDA, respiratory inhalers are classified under Class II medical devices. All inhaled products have to undergo mandatory test for extractables, leachables and microbial contaminants. Specific tests for OINDPs include aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). These tests are regarded as key parameters for assessing performance of the OINDPs. In addition, nasal sprays and MDIs are supplemented by tests to monitor the performance of the actuator and metering valve such as plume geometry and spray pattern.

Restraints of the Global Pulmonary Drug Delivery Systems Market

Major factors hampering the growth of the pulmonary drug delivery systems market during the forecast period constitutes of stringent regulations, and complications in use.

Key features of the study:

• This report provides in-depth analysis of the global pulmonary drug delivery systems market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019-2027), considering 2018, as the base year

• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

• It profiles leading players in the global pulmonary drug delivery systems market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans

• Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.

• Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics

• The global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

• Global Pulmonary Drug Delivery Systems Market, By Product Type:
  • Nebulizers
  • MDIs
  • DPIs
• Global Pulmonary Drug Delivery Systems Market, By Application:
  • Asthma
  • COPD
  • Cystic Fibrosis
• Global Pulmonary Drug Delivery Systems Market, By Geography:
  • North America
  • By Product Type
• Nebulizers
• MDIs
• DPIs
  • By Application
• Asthma
• COPD
• Cystic Fibrosis
  • By Country:
• U.S.
• Canada
  • Europe
  • By Product Type
• Nebulizers
• MDIs
• DPIs
  • By Application
• Asthma
• COPD
• Cystic Fibrosis
  • By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
  • Asia Pacific
  • By Product Type
• Nebulizers
• MDIs
• DPIs
  • By Application
• Asthma
• COPD
• Cystic Fibrosis
  • By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
  • Latin America
  • By Product Type
• Nebulizers
• MDIs
• DPIs
  • By Application
• Asthma
• COPD
• Cystic Fibrosis
  • By Country
• Brazil
• Argentina
• Mexico
• Rest of LATAM
  • Middle East:
  • By Product Type
• Nebulizers
• MDIs
• DPIs
  • By Application
• Asthma
• COPD
• Cystic Fibrosis
  • By Country:
• GCC
• Israel
• Rest of Middle East
  • Africa
  • By Product Type
• Nebulizers
• MDIs
• DPIs
  • By Application
• Asthma
• COPD
• Cystic Fibrosis
  • By Country/Region:
• Central Africa
• South Africa
• North Africa
• Company Profiles
  • 3M Health Care*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Allied Healthcare Products, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim
  • CareFusion Corporation
  • GF Health Products, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Healthcare, Inc.
  • Glenmark Pharmaceuticals
  • PARI Respiratory Equipment, Inc.
  • Philips Healthcare

^"*" marked represents similar segmentation in other categories in the respective section.